このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome (NEURDS)

2026年6月1日 更新者:University Hospital, Angers

Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë

Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.

Its management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.

Improvements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.

Although essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).

The use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.

Among the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.

In addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term "ventilator-associated brain injury" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.

During brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.

Clinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA score, and the MMSE in patients with OSA or COPD, respectively, indicating an association between this protein and cognitive impairment.

We therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.

調査の概要

研究の種類

介入

入学 (推定)

150

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Adult patient
  • Patient admitted to the intensive care unit less than 48 hours ago
  • Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂/FiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:

    • Mild ARDS: 200 < PaO₂/FiO₂ < 300 mmHg
    • Moderate ARDS: 100 < PaO₂/FiO₂ < 200 mmHg
    • Severe ARDS: PaO₂/FiO₂ < 100 mmHg
  • Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)
  • Patients registered with or covered by a social security scheme
  • Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).

Exclusion Criteria:

  • Patients with a history of central nervous system disorders resulting in cognitive impairment

    • Patients on ECMO
    • Patients admitted for symptomatic central nervous system disorders
    • Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.
    • Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.
    • Pregnant, breastfeeding or labouring patients
    • Individuals subject to a legal protection order
    • Individuals receiving compulsory psychiatric care
    • Individuals deprived of their liberty by judicial or administrative decision

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Exploratory arm
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
to determine whether there is an association between the mechanical power between Day 1 and Day 3 (reflecting the risk of VILI)
時間枠:at day 1, day 2 and day 3
mechanical power calculation
at day 1, day 2 and day 3
to determine serum S-100B protein level between Day 1 (H0) and Day 3 (H72).
時間枠:at day 1, day 2 and day 3
S-100B protein dosage
at day 1, day 2 and day 3

二次結果の測定

結果測定
メジャーの説明
時間枠
To investigate the association between serum S100B protein concentrations from day 1 to day 3 and neurological outcome at 3 months and 12 months
時間枠:at 3 and 12 months
Correlation coefficient between S-100B protein levels from Day 1 to Day 3 and the MOCA score at 3 and 12 months (no neurocognitive impairment if MOCA ≥ 26/30, neurocognitive impairment if < 25/30).
at 3 and 12 months
To investigate the association between other VILI markers (inspiratory transpulmonary pressure and driving pressure) and serum S100B protein concentrations from day 1 to day 3.
時間枠:From day 1 to day 3
Correlation coefficient between inspiratory transpulmonary pressure and driving pressure, and serum S-100B levels between Day 1 and Day 3, whilst accounting for potential confounding factors in a multivariate model
From day 1 to day 3
To investigate the association between these other VILI markers and neurological outcomes at 3 months and 12 months.
時間枠:at 3 and 12 months
Correlation coefficient between mechanical power, inspiratory transpulmonary pressure and driving pressure (average of values measured between J1 and J3) and the MOCA score at 3 and 12 months, taking potential confounding factors into account in a multivariate model
at 3 and 12 months
To investigate the association between the occurrence of delirium during a stay in the intensive care unit and neurological outcomes at 3 and 12 months.
時間枠:at 3 and 12 months
The occurrence of neurocognitive impairment, defined as a MoCA score of <25/30 at the 3- and 12-month assessments, in patients who experienced delirium in the intensive care unit compared with those who did not.
at 3 and 12 months
Describe the prevalence of depression (PHQ-9 score) among patients who presented ARDS
時間枠:at 3 months
occurrence of depressive symptoms (defined as a PHQ-9 score > 10)
at 3 months
Describe the prevalence of post-traumatic stress (PCL-5 score) among patients who presented ARDS
時間枠:at 3 months
occurrence of post-traumatic stress (defined as a PCL-5 score > 33)
at 3 months
Describe the prevalence of anxiety (GAD-2 score) among patients who presented ARDS
時間枠:at 3 months
anxiety disorders (defined as a GAD-2 score > 3)
at 3 months
Describe the decline in quality of life (Euro 5d 5l score) among patients who presented ARDS
時間枠:at 3 months
deterioration in quality of life (EuroQol-5D-5L score analysed both continuously and categorically)
at 3 months
Describe the prevalence of independence (IADL) among patients who presented ARDS
時間枠:at 3 months
occurence of a decline in functional independence (defined as the loss of at least one instrumental activity compared with the level prior to hospitalisation)
at 3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月17日

一次修了 (推定)

2028年10月23日

研究の完了 (推定)

2029年10月23日

試験登録日

最初に提出

2026年6月1日

QC基準を満たした最初の提出物

2026年6月1日

最初の投稿 (実際)

2026年6月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月5日

QC基準を満たした最後の更新が送信されました

2026年6月1日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 49RC25_0292

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

IPD 共有時間枠

The data will be shared after signing a negotiated data transfer agreement ( data access agreement), for the duration specified in the agreement.

IPD 共有アクセス基準

The data will be made available via secure transfer (sharing platform approved by the university hospital: BlueFiles or Oodrive).

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する